The offering totals $400,000,000 before costs, with net proceeds estimated at $368.8 million. The prospectus keeps the going-concern warning and says no pivotal trial has finished.
The S-1 leaves the share count and price range blank. Management and the auditor say cash will not last twelve months, which raises going-concern doubt.
Questions about Generate Biomedicines
Has Generate Biomedicines issued a going-concern warning?
Our latest story on this, dated Feb 27, 2026: "Generate Biomedicines prices IPO of 25,000,000 shares at $16.00". The story links the filing or release it is based on. Read the story.
When did Generate Biomedicines go public?
Our latest story on this, dated Feb 27, 2026: "Generate Biomedicines prices IPO of 25,000,000 shares at $16.00". The story links the filing or release it is based on. Read the story.
Has Generate Biomedicines raised money recently?
Our latest story on this, dated Feb 27, 2026: "Generate Biomedicines prices IPO of 25,000,000 shares at $16.00". The story links the filing or release it is based on. Read the story.
What is the ticker symbol of Generate Biomedicines?
Generate Biomedicines, Inc. trades under the ticker GENB on NASDAQ.
Where is Generate Biomedicines listed?
Generate Biomedicines, Inc. is listed on NASDAQ. Our directory also records these other listings: BMV:GENB.
What is the SEC CIK of Generate Biomedicines?
The SEC Central Index Key (CIK) for Generate Biomedicines, Inc. is 2100782. Its filings are on SEC EDGAR.
How many shares does Generate Biomedicines have outstanding?
128,352,436 shares as of 2026-07-29, per the cover page of its 10-Q filed 2026-08-06.
Which country or territory is Generate Biomedicines listed under?
Our directory records Generate Biomedicines, Inc. under United States.
What does Generate Biomedicines do?
Our directory classifies Generate Biomedicines, Inc. as: Biotechnology. This is a directory classification, not a description of the pipeline.
What is the ISIN of Generate Biomedicines?
The ISIN recorded for Generate Biomedicines, Inc. is US3709201004.
Does aibio.space cover Generate Biomedicines?
aibio.space lists Generate Biomedicines, Inc. among 2,820 public biotech companies and publishes its news here as stories appear.
Where is Generate Biomedicines incorporated?
SEC records list its state or country of incorporation as DE.
What is the latest Generate Biomedicines (GENB) stock news?
Our latest story on Generate Biomedicines, dated Feb 27, 2026: "Generate Biomedicines prices IPO of 25,000,000 shares at $16.00". The offering totals $400,000,000 before costs, with net proceeds estimated at $368.8 million. The prospectus keeps the going-concern warning and says no pivotal trial has finished. Source.
How long will Generate Biomedicines's cash last?
From our story of Feb 27, 2026: The prospectus keeps the going-concern warning and says no pivotal trial has finished. Source.
How much cash does Generate Biomedicines have?
From our story of Feb 27, 2026: The company had approximately $221.5 million in cash, cash equivalents, restricted cash and marketable securities at December 31, 2025. Source.
Investor discussion: Generate Biomedicines
Members talk about Generate Biomedicines (GENB). Reader posts, not aibio.space reporting, and not investment advice.
Rules
Securities violations are strictly forbidden. No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information.
Say whether you hold the stock. Every post states long, short or no position.
No paid or sponsored posts. Do not post for anyone who pays or rewards you.
No buy or sell calls and no price targets.
No accusations of crime or fraud against named people unless you link a court filing or a regulator's release that makes them.
No personal details and no spam. No links at all for your first 7 days as a member.
Posts that break the rules may be deleted without notice, and the account restricted or closed. See the terms and the privacy policy.
Capital-markets timeline
Financings, listing notices, splits, legal actions and other investor events at Generate Biomedicines, newest first. Each line links the filing it comes from.
Distress
Reported substantial doubt about its ability to continue as a going concern. SEC Form 10-Q. Source
Financings
Filed a final prospectus for a securities offering. SEC Form 424B4. Source
Financings
Filed a registration statement for a share offering. SEC Form S-1. Source
Stock chart
Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. Open NASDAQ:GENB on TradingView.
SEC filings and registration
SEC name
Generate Biomedicines, Inc.
CIK
2100782
Industry (SIC)
Pharmaceutical Preparations (2834)
US tickers
GENB (Nasdaq)
State or country of incorporation
DE
Fiscal year ends
December 31
Filer category
<br>Emerging growth company
Business address
101 SOUTH STREET, SUITE 900, SOMERVILLE, MA, 02143
Phone
888-469-0055
Shares outstanding
128,352,436 as of 2026-07-29 (10-Q filed 2026-08-06)
Recent filings (8-K and 6-K are the company's own announcements)
Source: SEC EDGAR, retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices.
Listing details
Generate Biomedicines, Inc. is a public biotech or pharmaceutical company listed on NASDAQ under the ticker GENB, recorded under United States. The directory classifies it as Biotechnology. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them.
Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. Tell us about a change. Work at this company? Claim this page.
Published and maintained by aibio.space. Not investment advice. How we work.
Who manages this pageThis page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction
aibio